Alzheimer’s Drugs Market By Phase 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Alzheimer’s Drugs Market
Alzheimer’s Drugs Market Analysis: By Phase (Phase-I, Phase-II, Phase-III and Others); By Drug Type (NMDA Receptor Antagonist, Acetylcholinesterase Inhibitor) and Geography – Forecast to 2021
Report Code : HCR 0112
Published: 25 February, 2016   No. of pages: 138

  • Report Description
  • Table of Contents
  • Customization Options
Alzheimer’s disease is classified as a progressive neurological disease that affects the functioning of the brain, ultimately leading to neuron loss. It is a neurodegenerative disease of the brain which leads to loss of memory and cognitive functions. Alzheimer’s treatment is a high risk, high reward market which has a huge revenue generating potential.

This report identifies the Alzheimer’s Drugs market size in terms of value for the year 2014-2016, and forecast of the same for year 2021. It highlights potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to Alzheimer’s Drugs market.
  • This report has been divided based on drug type which includes NMDA Receptor Antagonist and Acetylcholinesterase Inhibitor.
  • This report also includes Alzheimer’s Drugs market by Phases, which includes Phase-I, Phase-II, Phase-III and Others.
  • This report has been further segmented into major regions, which includes detailed analysis of each region such as Americas, Europe, Asia-Pacific (APAC) and Rest of the World (RoW).  Country level markets for each of the regions are also analyzed and determined.
The major countries considered under the Americas region are Argentina, Brazil and the North American region. The major countries considered under the Asia-Pacific region are China, Japan, India, South Korea and others. The major countries considered under the European region are United Kingdom, France, Germany and others.

Alzheimer’s Drugs Market

Globally demand for Alzheimer’s Drugs is expected to witness growth in the upcoming future due to growing prevalence of the neurological disorder in the geriatric population, increasing average life span of people and the aging population. The major factor restraining the substantial growth of Alzheimer’s Drugs is the lack of techniques for diagnosing or treating Alzheimer’s disease. The major factor challenging the substantial growth of Alzheimer’s Drugs is the difficulty involved in the early diagnosis of indication of Alzheimer’s disease. North America and Europe has the highest markets share by value in global Alzheimer’s Drugs market and Asia Pacific region is projected to have a significant growth during the forecast period.

This market research report includes in depth analysis of Alzheimer’s Drugs in each application and in the regional segment separately to provide in depth view of key insights and market scenario. Forecasts are also provided for all the market segments for the period 2016-2021.

This report also includes detailed profiling of following the major players in the global Alzheimer’s Drugs market:
  • Eli Lilly
  • GE Healthcare
  • Bayer Pharmaceuticals
  • Genentech
  • Roche
1. Alzheimer’s Drugs – Market Overview
2. Executive Summary
3. Alzheimer’s Drugs – Market Landscape

   3.1. Market Share Analysis
   3.2. Comparative Analysis
      3.2.1. Product Benchmarking
      3.2.2. End User Profiling
      3.2.3. Top 5 Financials Analysis
4. Alzheimer’s Drugs– Market Forces
   4.1. Market Drivers
      4.1.1. Growing prevalence of the neurological disorder in the geriatric population
      4.1.2. Increasing average life span of people
      4.1.3. Aging population
   4.2. Market Constraints
      4.2.1. Lack of techniques for diagnosing or treating Alzheimer’s disease
   4.3. Market Challenges
      4.3.1. Early Diagnosis of the Indication is Challenging
   4.4. Attractiveness of the Alzheimer’s Drugs Industry
      4.4.1. Power of Suppliers
      4.4.2. Power of Customers
      4.4.3. Threat of New Entrants
      4.4.4. Threat of Substitution
      4.4.5. Degree of Competition
5. Alzheimer’s Drugs Market – Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunities Analysis
   5.4. Product/Market Life Cycle Analysis
   5.5. Suppliers and Distributors
6. Alzheimer’s Drugs Market – By Drug Type
   6.1. NMDA Receptor Antagonist
   6.2. Acetylcholinesterase Inhibitor
7. Alzheimer’s Drugs Market – By Phase
   7.1. Phase-I
   7.2. Phase-II
   7.3. Phase-III and
   7.4. Others
8. Alzheimer’s Drugs Market - By Geography
   8.1. Introduction
   8.2. Global Study
   8.3. Americas
      8.3.1. North America
      8.3.2. Brazil
      8.3.3. Argentina
      8.3.4. Others
   8.4. Europe
      8.4.1. U.K.
      8.4.2. France
      8.4.3. Germany
      8.4.4. Others
   8.5. APAC
      8.5.1. China
      8.5.2. South Korea
      8.5.3. Japan
      8.5.4. India
      8.5.5. Others
   8.6. ROW
9. Alzheimer’s Drugs Market Market Entropy
   9.1. New Product Launches
   9.2. M&As, Collaborations, JVs and Partnerships
10. Company Profiles
   10.1. Roche
      10.1.1. Introduction
      10.1.2. Financials
      10.1.3. Key Insights
      10.1.4. Key Strategy
      10.1.5. Product Portfolio
      10.1.6. SWOT Analysis
   10.2. Genentech
      10.2.1. Introduction
      10.2.2. Financials
      10.2.3. Key Insights
      10.2.4. Key Strategy
      10.2.5. Product Portfolio
      10.2.6. SWOT Analysis
   10.3. Novartis
      10.3.1. Introduction
      10.3.2. Financials
      10.3.3. Key Insights
      10.3.4. Key Strategy
      10.3.5. Product Portfolio
      10.3.6. SWOT Analysis
   10.4. Eli Lilly
      10.4.1. Introduction
      10.4.2. Financials
      10.4.3. Key Insights
      10.4.4. Key Strategy
      10.4.5. Product Portfolio
      10.4.6. SWOT Analysis
   10.5. GE Healthcare
      10.5.1. Introduction
      10.5.2. Financials
      10.5.3. Key Insights
      10.5.4. Key Strategy
      10.5.5. Product Portfolio
      10.5.6. SWOT Analysis
   10.6. Eisai
      10.6.1. Introduction
      10.6.2. Financials
      10.6.3. Key Insights
      10.6.4. Key Strategy
      10.6.5. Product Portfolio
      10.6.6. SWOT Analysis
   10.7. Bayer Pharmaceuticals
      10.7.1. Introduction
      10.7.2. Financials
      10.7.3. Key Insights
      10.7.4. Key Strategy
      10.7.5. Product Portfolio
      10.7.6. SWOT Analysis
   10.8. Merck
      10.8.1. Introduction
      10.8.2. Financials
      10.8.3. Key Insights
      10.8.4. Key Strategy
      10.8.5. Product Portfolio
      10.8.6. SWOT Analysis
   10.9. Navidea
      10.9.1. Introduction
      10.9.2. Financials
      10.9.3. Key Insights
      10.9.4. Key Strategy
      10.9.5. Product Portfolio
      10.9.6. SWOT Analysis
   10.10. Diagenic
      10.10.1. Introduction
      10.10.2. Financials
      10.10.3. Key Insights
      10.10.4. Key Strategy
      10.10.5. Product Portfolio
      10.10.6. SWOT Analysis
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
11. Appendix

   11.1. Abbreviations
   11.2. Sources
   11.3. Research Methodology
   11.4. Bibliography
   11.5. Compilation of Expert Insights
   11.6. Disclaimer
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports